https://www.contagionlive.com/view/sulopenem-narrowly-misses-primary-end-point-in-phase-3-ciai-study
Sulopenem Narrowly Misses Primary End Point in Phase 3 cIAI Study | Contagion Live
Oct 15, 2026 - The difference in outcomes was 4.7% with a 95% confidence interval on that difference of -10.3% to 1.0%. This fell short of non-inferiority which required that...
primary end pointsulopenemnarrowlymissesphase